PARTICULARS TO APPEAR ON THE OUTER PACKAGE (Box of 2 x 1 bottle, 2 x 10 bottles and 2 x 50 bottles)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Eurican Herpes 205 powder and solvent for emulsion for injection

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Per 1 ml dose:
Canine herpesvirus (F205 strain) antigens 0.3 to 1.75 mcg*
*expressed in mcg of gB glycoproteins

3. PACKAGE SIZE

1 dose: 1 x 1 dose powder + 1 x 1 ml solvent
10 doses: 10 x 1 dose powder + 10 x 1 ml solvent
50 doses: 50 x 1 dose powder + 50 x 1 ml solvent

4. TARGET SPECIES

Dogs.

5. INDICATION(S)

6. ROUTES OF ADMINISTRATION

Subcutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {dd/mm/yyyy}
Once reconstituted use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Store in a refrigerator.
Do not freeze.
Protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH

14. MARKETING AUTHORISATION NUMBERS

Vm 04491/5008

15. BATCH NUMBER

Lot {number}

16. SPECIAL WARNING(S), IF NECESSARY

17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: Read package leaflet.

18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

(Veterinary medical product subject to prescription).

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS (bottle (glass) vaccine)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Eurican Herpes 205

2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

1 dose

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {dd/mm/yyyy}

5. ROUTE(S) OF ADMINISTRATION

6. THE WORDS “FOR ANIMAL TREATMENT ONLY”

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS (bottle 1 ml solvent)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Eurican Herpes 205 solvent

2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

1 ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

5. ROUTE(S) OF ADMINISTRATION

6. THE WORDS “FOR ANIMAL TREATMENT ONLY”

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Eurican Herpes 205 powder and solvent for emulsion for injection.

2. COMPOSITION

Per 1 ml dose:

Lyophilisate:
Active substance:

Canine herpesvirus (F205 strain) antigens	0.3 to 1.75 mcg*

*expressed in mcg of gB glycoproteins

Solvent:
Adjuvant:

Light paraffin oil	224.8 to 244.1 mg

Lyophilisate: white pellet.
Solvent: homogeneous white emulsion.

3. TARGET SPECIES

Dogs.

4. INDICATIONS FOR USE

Active immunisation of pregnant bitches to prevent mortality, clinical signs and lesions in puppies resulting from canine herpes virus infections acquired in the first few days of life through passive immunity.

Onset of immunity: the passive immunity in puppies born from vaccinated bitches starts with sufficient colostrum intake.

Duration of immunity: first few days of life.

5. CONTRAINDICATIONS

None.

6. SPECIAL WARNINGS

Vaccinate healthy animals only.
Abortion and premature parturition can occur as a result of CHV infection in bitches, the protection of the bitch against infection has not been studied for this vaccine. In order for immunity to be conferred to the puppies, sufficient intake of colostrum is required.

Special precautions to be taken by the person administrating the veterinary medicinal product to animals:
To the user:
This product contains mineral oil. Accidental injection/self-injection may result in severe

pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package insert with you.
If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:
This product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Pregnancy:
This vaccine is specifically indicated during pregnancy.

Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:
No adverse effects other than those listed in section “Adverse events” have been observed after the administration of a 2-fold overdose.

Major incompatibilities:
Do not mix with any other veterinary medicinal product except the solvent supplied for use with the veterinary medicinal product.

7. ADVERSE EVENTS

Dogs:

Common (1 to 10 animals / 100 animals treated):
Injection site swelling.[1]
Rare (1 to 10 animals / 10 000 animals treated):
Hypersensitivity reaction.[2]

[1] Transient. Usually regressing within one week.
[2] Appropriate symptomatic treatment should be administered.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package

leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: (https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine).

8. DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION

Following reconstitution of the powder with the solvent, inject one dose (1 ml) of the vaccine via the subcutaneous route, according to the following schedule:

First injection:	Either during heat or 7 to 10 days after the presumed date of mating.
Second injection:	1 to 2 weeks before the expected date of whelping.
Revaccination:	During each pregnancy, according to the same schedule.

9. ADVICE ON CORRECT ADMINISTRATION

Aseptically reconstitute the contents of the powder with the solvent supplied with this vaccine.
The reconstituted content shall be a milky emulsion.

10. WITHDRAWAL PERIODS

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protect from light.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after “Exp.”.
Shelf life after reconstitution according to directions: use immediately.

12. SPECIAL PRECAUTIONS FOR DISPOSAL

Medicines should not be disposed of via wastewater. These measures should help to protect the environment.
Any unused veterinary medical product or waste materials derived from such veterinary medical product should be disposed in accordance with local requirements.

13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 04491/5008

Box of 2 x 1 bottle, 2 x 10 bottles and 2 x 50 bottles.
Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. CONTACT DETAILS

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
Germany

Manufacturer responsible for batch release:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint-Priest
France

Local representatives and contact details to report suspected adverse reactions:
United Kingdom (Great Britain)
Boehringer Ingelheim Animal Health UK Ltd., United Kingdom
Tel: + 44 1344 746957

17. OTHER INFORMATION

Purified subunit vaccine for the active immunisation of pregnant bitches to induce passive immunity in puppies against herpesvirus-induced fatal neonatal disease.

POM-V

Approved 20 November 2024
Gavin Hall